Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial
Adlai Nortye (ANL) partnered with Lilly (LLY) and Merck KGaA for a trial of its cancer drug AN4035. Lilly and Merck will supply cetuximab for free in the US, Australia, and China. AN4035 targets colorectal, pancreatic, and lung cancers. ANL's stock is down 25.96% over 20 days, closing at $11.61 on the announcement day.
How this was made
The 30-second read
Why it matters
The collaboration validates AN4035's mechanism but immediate price reaction was muted; investors may watch short‑interest dynamics and upcoming trial data.
Market read
Primary biotech news with modest immediate impact; relevance for traders lies in monitoring trial outcomes and short‑interest pressure.
What to watch
Future data from the AN4035 trial and upcoming AN9025 readout could drive significant re‑rating.
Background
Adlai Nortye (ANL) announced a clinical trial partnership with Eli Lilly (LLY) and Merck KGaA, supplying cetuximab for its AN4035 ADC candidate.
Ticker impact
Adlai Nortye disclosed a new clinical trial collaboration and supply agreement with Eli Lilly and Merck KGaA for its experimental cancer drug AN4035.
slight upside pressure as investors assess trial potential
Trial collaboration is material for a biotech micro‑cap, yet short interest remains high and price reaction was muted.
Eli Lilly will supply cetuximab at no cost for the AN4035 trial, marking its involvement in the collaboration.
no material impact on LLY price
Supply agreement is a small, non‑financial contribution to a partner's trial.
Market effects
Adds a new RAS‑targeting trial to the biotech pipeline, modestly supporting the oncology sector.
US biotech investors may note the trial expansion to Australia and China.
Limited to niche biotech investors; no broad market effect.
Counterpoint
High short interest suggests the market may be underpricing potential upside if trial data prove positive.
Key entities
- CompanyAdlai Nortye Group Ltd
Biotech firm developing AN4035
- CompanyEli Lilly and Company
Supplies cetuximab for the trial
- CompanyMerck KGaA
Supplies cetuximab for sites in Australia and China
